Literature DB >> 28640258

Effects of a ketamine metabolite on synaptic NMDAR function.

Kanzo Suzuki1, Elena Nosyreva1, Kevin W Hunt2, Ege T Kavalali1, Lisa M Monteggia1.   

Abstract

Entities:  

Year:  2017        PMID： 28640258     DOI： 10.1038/nature22084

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  13 in total

1.  Antidepressant effects of ketamine in depressed patients.

Authors:  R M Berman; A Cappiello; A Anand; D A Oren; G R Heninger; D S Charney; J H Krystal
Journal:  Biol Psychiatry       Date:  2000-02-15       Impact factor: 13.382

2.  The route of absorption of intraperitoneally administered compounds.

Authors:  G Lukas; S D Brindle; P Greengard
Journal:  J Pharmacol Exp Ther       Date:  1971-09       Impact factor: 4.030

3.  Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Irving W Wainer; Edson X Albuquerque; Scott M Thompson; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Biol Psychiatry       Date:  2016-09-30       Impact factor: 13.382

4.  Spontaneous and evoked glutamate release activates two populations of NMDA receptors with limited overlap.

Authors:  Deniz Atasoy; Mert Ertunc; Krista L Moulder; Justin Blackwell; ChiHye Chung; Jianzhong Su; Ege T Kavalali
Journal:  J Neurosci       Date:  2008-10-01       Impact factor: 6.167

5.  Acute suppression of spontaneous neurotransmission drives synaptic potentiation.

Authors:  Elena Nosyreva; Kristen Szabla; Anita E Autry; Alexey G Ryazanov; Lisa M Monteggia; Ege T Kavalali
Journal:  J Neurosci       Date:  2013-04-17       Impact factor: 6.167

6.  Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses.

Authors:  Erinn S Gideons; Ege T Kavalali; Lisa M Monteggia
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-27       Impact factor: 11.205

7.  Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.

Authors:  Jaskaran B Singh; Maggie Fedgchin; Ella Daly; Liwen Xi; Caroline Melman; Geert De Bruecker; Andre Tadic; Pascal Sienaert; Frank Wiegand; Husseini Manji; Wayne C Drevets; Luc Van Nueten
Journal:  Biol Psychiatry       Date:  2015-11-03       Impact factor: 13.382

8.  Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors.

Authors:  Ruin Moaddel; Galia Abdrakhmanova; Joanna Kozak; Krzysztof Jozwiak; Lawrence Toll; Lucita Jimenez; Avraham Rosenberg; Thao Tran; Yingxian Xiao; Carlos A Zarate; Irving W Wainer
Journal:  Eur J Pharmacol       Date:  2012-11-23       Impact factor: 4.432

9.  Antidepressant Actions of Ketamine Versus Hydroxynorketamine.

Authors:  Graham L Collingridge; Yeseul Lee; Zuner A Bortolotto; Heather Kang; David Lodge
Journal:  Biol Psychiatry       Date:  2016-09-28       Impact factor: 13.382

10.  NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Polymnia Georgiou; Jonathan Fischell; Greg I Elmer; Manickavasagom Alkondon; Peixiong Yuan; Heather J Pribut; Nagendra S Singh; Katina S S Dossou; Yuhong Fang; Xi-Ping Huang; Cheryl L Mayo; Irving W Wainer; Edson X Albuquerque; Scott M Thompson; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Nature       Date:  2016-05-04       Impact factor: 49.962
View more
  65 in total

Review 1.  The impact of sex as a biological variable in the search for novel antidepressants.

Authors:  Alexia V Williams; Brian C Trainor
Journal:  Front Neuroendocrinol       Date:  2018-05-31       Impact factor: 8.606

2.  Hydroxynorketamine Blocks N-Methyl-d-Aspartate Receptor Currents by Binding to Closed Receptors.

Authors:  Jamie A Abbott; Gabriela K Popescu
Journal:  Mol Pharmacol       Date:  2020-06-29       Impact factor: 4.436

Review 3.  Targeting Homeostatic Synaptic Plasticity for Treatment of Mood Disorders.

Authors:  Ege T Kavalali; Lisa M Monteggia
Journal:  Neuron       Date:  2020-06-03       Impact factor: 17.173

Review 4.  Engaging homeostatic plasticity to treat depression.

Authors:  E R Workman; F Niere; K F Raab-Graham
Journal:  Mol Psychiatry       Date:  2017-11-14       Impact factor: 15.992

Review 5.  Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine.

Authors:  Liana Fattore; Alessandro Piva; Mary Tresa Zanda; Guido Fumagalli; Cristiano Chiamulera
Journal:  Psychopharmacology (Berl)       Date:  2017-11-25       Impact factor: 4.530

Review 6.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 7.  Ketamine: The final frontier or another depressing end?

Authors:  Omar K Sial; Eric M Parise; Lyonna F Parise; Tamara Gnecco; Carlos A Bolaños-Guzmán
Journal:  Behav Brain Res       Date:  2020-02-01       Impact factor: 3.332

8.  Spontaneous neurotransmission: A form of neural communication comes of age.

Authors:  Ege T Kavalali
Journal:  J Neurosci Res       Date:  2017-12-08       Impact factor: 4.164

9.  Sex differences in sub-anesthetic ketamine's antidepressant effects and abuse liability.

Authors:  Katherine N Wright; Mohamed Kabbaj
Journal:  Curr Opin Behav Sci       Date:  2018-03-02

10.  Ketamine administration during a critical period after forced ethanol abstinence inhibits the development of time-dependent affective disturbances.

Authors:  Oliver Vranjkovic; Garrett Winkler; Danny G Winder
Journal:  Neuropsychopharmacology       Date:  2018-05-24       Impact factor: 7.853
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.